Uncategorized
VIDEO: Hydrus looks to be next MIGS device in US market
NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Dave Van Meter, president and CEO of Ivantis, discusses the Hydrus microstent, which has a “trimodal” mechanism of action to lower IOP in patients with glaucoma.